Antithrombotic therapy after myocardial reperfusion in acute myocardial infarction.
The problem of post-thrombolytic reocclusion can be approached in several ways. 1) Better thrombolytic agents with longer duration of effects and more powerful properties aimed at enhanced clot lysis and anticoagulation are under study. 2) The combination of high dose heparin and low dose aspirin is proposed for all patients with an acute myocardial infarction treated with thrombolytic agents. 3) Peptide inhibitors of thrombin and monoclonal antibodies against platelet glycoprotein receptors and adhesive macromolecules are potentially effective inhibitors of platelet aggregation and thrombus formation during or after thrombolytic therapy.
Fuster
V
V
Division of Cardiology, Mount Sinai Medical Center, New York, New York 10029.
Stein
B
B
Badimon
L
L
Chesebro
J H
JH
D003327:Coronary Disease / Q000628:therapy*; D003328:Coronary Thrombosis / Q000150:complications / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D015425:Myocardial Reperfusion; D010974:Platelet Aggregation; D012008:Recurrence
D005343:Fibrinolytic Agents